The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $141.41

Today's change0.00 0.00%
Updated May 1 4:08 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $141.41

Today's change0.00 0.00%
Updated May 1 4:08 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd closed at (U.S.)$141.41.

Over the last five days, shares have lost 2.87% and are down 4.58% for the last year to date. This security has outperformed the S&P 500 by 12.24% during the last year.

Key company metrics

  • Open(U.S.) $140.69
  • Previous close(U.S.) $141.41
  • High(U.S.) $142.99
  • Low(U.S.) $140.26
  • Bid / Ask-- / --
  • YTD % change-4.58%
  • Volume72,334
  • Average volume (10-day)75,137
  • Average volume (1-month)69,238
  • Average volume (3-month)72,379
  • 52-week range(U.S.) $103.33 to (U.S.) $173.00
  • Beta0.49
  • Trailing P/E15.52×
  • P/E 1 year forward13.32×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $9.11
Updated May 1 4:08 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+50.61%

Based on its net profit margin of 50.61%, Taro Pharmaceutical Industries Ltd is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.76%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue251130187214
Total other revenue--------
Total revenue251130187214
Gross profit19885141172
Total cost of revenue53454641
Total operating expense91768679
Selling / general / administrative22222722
Research & development14151315
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)2-701
Other operating expenses, total--------
Operating income16054102135
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax17051107139
Income after tax1444690116
Income tax, total2651724
Net income1434690116
Total adjustments to net income--------
Net income before extra. items1444690116
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1444690116
Inc. avail. to common incl. extra. items1434690116
Diluted net income1434690116
Dilution adjustment----0--
Diluted weighted average shares43434345
Diluted EPS excluding extraordinary itemsvalue per share3.351.082.092.59
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share3.400.942.092.60